I'm LongbridgeAI, I can summarize articles.Guggenheim maintains a Buy rating on Elevance Health with a $485 price target, implying an 11.7% upside from the Oct 21 close of $434.13. The firm cites strong earnings growth potential driven by Medicaid margin improvements, favorable ACA claims experience, and Carelon services expansion. Additionally, Elevance's robust market position as the largest Blue Cross Blue Shield provider, bolstered by acquisitions like Amerigroup and MMM, supports future growth opportunities.
Guggenheim maintained their Buy rating on Elevance Health's stock with a price target of $485.00.
The price target implies an upside of 11.7% from the Oct 21 close of $434.13.
Key takeaways from the analyst note
Strong Earnings Growth Potential: Elevance Health is expected to achieve over 12% EPS growth due to a combination of Medicaid margin improvements, favorable claims experience in the ACA market, and ongoing growth in its Carelon services, which positions the company for sustained financial performance.
Robust Market Position and Strategic Acquisitions: As the largest provider of Blue Cross Blue Shield coverage and through strategic acquisitions like Amerigroup and MMM, Elevance has enhanced its presence in government-sponsored programs, solidifying its market position and driving future growth opportunities.
Explore more price target data and ratings for Elevance Health on the .